Metagenomics

搜索文档
Metagenomi (MGX) Earnings Call Presentation
2025-07-04 17:22
Forward Looking Statements Unlocking 4 Billion Years of Microbial Evolution to Create Curative Genetic Medicines Nasdaq: MGX May 2025 This presentation includes forward-looking statements, including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation are forward looking statements, including statements regarding our cash runway, strategy and plans, industry environment, ...
Metagenomi to Present at Upcoming Scientific Meetings
Globenewswire· 2025-05-02 19:00
文章核心观点 - 基因药物公司Metagenomi将在两个科学会议上进行展示,包括TIDES USA 2025的口头报告和ASGCT 2025年会的三个海报展示 [1] 公司信息 - Metagenomi是一家精准基因药物公司,致力于用AI驱动的宏基因组学平台为患者开发治愈性疗法 [3] - 公司利用宏基因组学解锁微生物进化成果,开发新型编辑工具,其基因组编辑工具包包括可编程核酸酶、碱基编辑器等 [3] 会议展示信息 TIDES USA 2025口头报告 - 标题为“AI-Guided Metagenomic Discovery of Compact CRISPR Systems for In Vivo Therapeutic Genome Editing” [2] - 会议主题为“Genome Editing Technologies and Applications”,地点在Mission Beach room [2] - 时间为2025年5月22日周四下午2:30 PST [2] ASGCT 2025年会海报展示 - 标题分别为“In Vivo Genome Editing with an Ultra-Compact Type V Nuclease for All-In-One AAV Delivery”“Site-Specific Integration of Therapeutic Transgenes with a Type V-K CAST System Engineered for Efficient and Targeted Human Genome Editing”“A Compact and Potent Type II CRISPR System for CNS Gene Knockdown via AAV Delivery” [2] - 摘要编号分别为AMA2219、AMA2184、AMA1232,地点均在Poster Hall I2 [2] - 时间均为2025年5月13日周二下午6:00 CT [2] - 所有展示内容将在公司网站投资者板块的“新闻与活动”页面公布 [2]